Source: Fox News
Summary
Dave Nitsche, a 57-year-old former Ironman triathlete, was diagnosed with stage 4 lung cancer after experiencing vision problems. Despite being given only 12-24 months to live, Nitsche has surpassed that timeframe by several years thanks to an experimental drug. He has been taking the drug Rybrevant (amivantamab) for a year, which has shown promising results. Nitsche’s case is rare, as lung cancer typically doesn’t spread to the eye. He credits his endurance training and high fitness level with helping to extend his survival.
Our Reading
The advice sounds familiar.
Rare cases of lung cancer can spread to unusual locations, such as the eye. Targeted therapies like afatinib and Tagrisso (osimertinib) can help manage the disease, but may eventually stop working. Experimental drugs like Rybrevant (amivantamab) offer new hope for patients. Nitsche’s experience highlights the importance of advocating for oneself and staying up-to-date with the latest therapies. As Nitsche says, “If you have lungs, you can get lung cancer – but at this point, for almost any type of cancer, a diagnosis is not a death sentence.”
Author: Evan Null
